510(k) device
Béa Applicator (BAP-GB-01)
Stepone Fertility Ltd (T/A Béa Fertility) · Cap, Cervical (HDR, Class II) · First FDA decision Apr 2, 2025, newest Apr 2, 2025Infertility
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "Béa"
MAUDE reports
0
Brand "Béa", since 2015
PubMed studies
1,105
Mentioning "Béa"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Béa Applicator (BAP-GB-01)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K242031 · Decided Apr 2, 2025 · 265 days after receipt
Device type: Cap, Cervical (HDR) · Obstetrics & Gynecology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Cervical Cancer with Human Papillomavirus (HPV) TestingNational analysisReview closedCAG-00442NUpdated Sep 22, 2026
- Positron Emission Tomography (FDG) for Cervical CancerNational analysisReview closedCAG-00181R2Updated Sep 21, 2026
- Positron Emission Tomography (FDG) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular CancersNational analysisReview closedCAG-00181NUpdated Sep 21, 2026
- Screening Pap Smears and Pelvic Examinations for Early Detection of Cervical or Vaginal CancerNational determinationOn the books210.2Updated Sep 30, 2025
- FDG PET for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers (Replaced with Section 220.6.17) - RETIREDNational determinationOn the books220.6.14Updated Jun 7, 2024
- Screening for Cervical Cancer with Human Papillomavirus (HPV)National determinationOn the books210.2.1Updated Jun 17, 2020
- Cervical FusionLocal determinationIn effectL39770Wellpoint FederalUpdated Jul 16, 2026
- Cervical FusionLocal determinationIn effectL39788WPS Insurance CorporationUpdated May 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Béa", any status and sponsor, newest update first.
StepOne FertilityNot on our public-company list
NCT05129553 · 40 participants (planned) · Start Mar 1, 2022 · Primary completion Aug 1, 2022
Device: Béa Applicator and Béa Cervical Cap Device · For: Safety and Usability
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Béa", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code HDR
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Béa"[tiab]. The summary above synthesizes these.
- Genotoxicity of beauvericin.
Knutsen HK, Åkesson A, Bampidis V, et al. · EFSA J · 2024
- The resting-state brain activity signatures for addictive disorders.
Zheng H, Zhai T, Lin X, et al. · Med · 2024Meta-Analysis, Research Support, Non-U.S. Gov't
- Beauvericin: The beauty and the beast.
Caloni F, Fossati P, Anadón A, et al. · Environ Toxicol Pharmacol · 2020Review
- Soymilk stability increase using polyphenols microcapsules.
Larrauri M, Asensio CM, Martín MP, et al. · J Food Sci Technol · 2024
- Effects of beauvericin on the blood cells of Bombyx mori.
Bi Y, Wu L, Li B, et al. · J Invertebr Pathol · 2023Research Support, Non-U.S. Gov't
- Robotic Revision of Hepaticojejunostomy for Benign Biliary Stricture.
Robinson J, Tschuor C, McKillop IH, et al. · Am Surg · 2023
- Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway.
Ye G, Jiao Y, Deng L, et al. · Int J Biol Sci · 2023Research Support, Non-U.S. Gov't
- Natural Occurrence and Co-Occurrence of Beauvericin and Enniatins in Wheat Kernels from China.
Xu W, Liang J, Zhang J, et al. · Toxins (Basel) · 2024Research Support, Non-U.S. Gov't
- Beauvericin Immunotoxicity Prevention by Gentiana lutea L. Flower In Vitro.
Di Matteo G, Cimbalo A, Manyes L, et al. · Toxins (Basel) · 2023Research Support, Non-U.S. Gov't
- Interaction of the Emerging Mycotoxins Beauvericin, Cyclopiazonic Acid, and Sterigmatocystin with Human Serum Albumin.
Fliszár-Nyúl E, Faisal Z, Skaper R, et al. · Biomolecules · 2022Research Support, Non-U.S. Gov't
- Collaborative Purification of Tert-Butanol and N2O over Fe/Co-Zeolite Catalysts.
Wu R, Liu N, Dai C, et al. · Int J Environ Res Public Health · 2023Research Support, Non-U.S. Gov't
- Fast one-step acrylate functionalization of hyaluronic acid via Williamson ether synthesis.
Milne C, Song R, Zhu R, et al. · Chem Commun (Camb) · 2024
Other devices of this type
Also filed under product code HDR.
- FERTI-LILY Conception CupRosesta Medical BV · 510(k) 2023
- Oves Cervical CapVeos , Ltd. · 510(k) 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.